



**Suppl. Figure 4. Metabolite levels stratified by disease and patient characteristics.** **A.** Levels of butyrate are lower in patients with CD and penetrating disease (Montreal B3) compared to non-structuring and non-penetrating forms of the disease (Montreal B1). **B.** In patients with UC, levels of 2R:3R-dihydroxybutyrate show a tendency to positively correlate with disease extension.